NBT Bank’s Royalty Pharma RPRX Stock Holding History

NBT Bank’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-34	Closed	-$1.91K	–	932
2026 Q2	$1.91K	Hold	34	–	–	﹤0.01%	874
2026 Q1	$1.63K	Buy	+34	New	+$1.49K	﹤0.01%	837

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

New South Capital Management Memphis, Tennessee $1.53B AUM 36.31% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

NBT Bank's RPRX Position: Q3 2026 in Review

NBT Bank sold out of Royalty Pharma (RPRX) in Q3 2026, closing a stake of 34 shares — an estimated $1.91K sold.

NBT Bank first reported a position in RPRX in Q1 2026 and held it in 2 quarters. The position peaked at $1.91K in Q2 2026. 318 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

NBT Bank reported no remaining Royalty Pharma position as of Q3 2026 after selling out during the quarter.
NBT Bank sold 34 Royalty Pharma shares in Q3 2026, an estimated $1.91K.
NBT Bank first reported a position in Royalty Pharma in Q1 2026 and held it in 2 quarters.
NBT Bank's Royalty Pharma position peaked at $1.91K in Q2 2026.
318 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on NBT Bank's 13F filing for Q3 2026, filed 21 Oct 2026.